Ma Y.,Hybio Pharmaceutical
Russian Journal of Biopharmaceuticals | Year: 2011
Recent advances in peptide drug field allow manufacturing of complex peptides on a very large scale. For purification of peptides, it is often difficult to use methods similar to those applied in the purification of other organic compounds, mainly due to their complexity. The high-pressure reversed phase preparative chromatography is the most efficiency in the industrial peptide purification process. The related introduction will be based on Hybio's experiences in this field.
Zhao J.-H.,Baise University |
Lin Y.-X.,Hybio Pharmaceutical |
Wu W.,Guangxi University for Nationalities |
Zhang Z.,Guangxi University for Nationalities
Acta Crystallographica Section E: Structure Reports Online | Year: 2012
In the centrosymmetric title compound, [Cu2(C10H 8O4)Cl2(C10H8N 2)2(H2O)2]·2H 2O, the CuII atom is five-coordinated in a distorted square-pyramidal geometry by two N atoms from a chelating 2,2′-bipyridine ligand, one O atom from a 1,4-phenyl-enediacetate ligand, one Cl atom and one water mol-ecule. The 1,4-phenyl-enediacetate ligand, lying on an inversion center, bridges two CuII atoms. In the crystal, O-H⋯O and O-H⋯Cl hydrogen bonds and π-π inter-actions between the pyridine rings [centroid-centroid distance = 3.740 (5) Å] link the complex mol-ecules and uncoordinated water mol-ecules into a three-dimensional network.
Yin Q.,Sun Yat Sen University |
Zhang Z.-G.,Zhongshan Peoples Hospital |
Ma Y.-P.,Hybio Pharmaceutical |
Li B.-F.,Zhongshan Peoples Hospital
Chinese Journal of Evidence-Based Medicine | Year: 2013
Objective To systematically review the effectiveness and safety of intracoronary glycoprotein IIb/IIIa inhibitors (GPIs) undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) compared with intravenous administration. Methods Databases including PubMed, EMbase, The Cochrane Library (Issue 9, 2012), Ovid, CBM, CNKI and VIP were electronically searched for randomized controlled trials (RCTs) about intracoronary GPIs administration versus intravenous administration undergoing PCI for ACS from inception to September 30th, 2012. Meanwhile, domestic relevant papers published in recent 1 year were also retrieved manually. References of the included studies were retrieved, too. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and assessed the methodologically quality of the included studies. Then, meta-analysis was performed using RevMan 5.1 software. Results 10 RCTs involving 3 553 ACS patients were finally included. The results of meta-analysis showed that: compared with intravenous administration, intracoronary GPIs administration decreased the major adverse cardiovascular event (MACE) (OR=0.54, 95%CI 0.34 to 0.85, P=0.008). The incidences of reinfarction (MI), revascularization (TVR) and heart failure were (OR=0.62, 95%CI 0.39 to 0.97, P=0.04), (OR=0.59, 95%CI 0.36 to 0.97, P=0.04), (OR=0.52, 95%CI 0.32 to 0.84, P=0.008), respectively. But for the mortality, there were no significant differences between the two groups (OR=0.81, 95%CI 0.58 to 1.14, P=0.23). Intravenous administration and intracoronary administration were alike in the incidences of mild/serious bleeding (mild: OR=0.94, 95%CI 0.75 to 1.19, P=0.63; serious: OR=1.18, 95%CI 0.76, 1.84, P=0.47). Conclusion Compared with routine GPIs regimen of intravenous bolus, intracoronary administration with initial dosage showed significant benefits in clinical outcomes in ACS patients undergoing PCI, which could not increase the incidence of bleeding. © 2013 Editorial Board of Chin J Evid-based Med.
Hybio Pharmaceutical | Date: 2014-03-13
Protein for industrial use; industrial chemicals; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for preserving foodstuffs; biological preparation for use in cell cultures other than for medical or veterinary use; plant growth regulating preparations; synthetic resins, unprocessed. Chemical reagents for medical or veterinary purposes; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; diagnostic preparations for medical purposes; dietetic foods, namely, pasta and crackers, adapted for medical use; veterinary preparations for treatment of intestinal bacteria; pesticides; biocides. Advertising services; commercial administration of the licensing of the goods and services of others; sales promotion for others provided through the distribution and the administration of privileged user cards; retail pharmacy services.
Hybio Pharmaceutical | Date: 2012-08-30
Provided is a method for solid phase synthesis of liraglutide, comprising the following steps: A), Fmoc-Gly-resin being obtained by coupling resin solid phase carrier with glycine with N-end protected by Fmoc(Fmoc-Gly-OH) in the presence of activator system; B) according to the peptide sequence of the main chain of liraglutide, successively coupling with amino acids with N-ends protected by Fmoc and protected side chains by the method for solid phase synthesis, wherein lysine employs Fmoc-Lys(Alloc)-OH; C) removing the protective group, Alloc, from the side chain of lysine; D) couplilng the side chain of lysine with Palmitoyl-Glu-Offiu by the method for solid phase synthesis; E) cleavage, removing protection groups and resin to obtain crude liraglutide; F) purifying and lyophilizing to obtain liraglutide.